Home / Blog / Isomorphic Labs raises $5 billion as it looks to take drug…
Tech News

Isomorphic Labs raises $5 billion as it looks to take drug candidates

Isomorphic Labs raised $5 billion in a Series C round led by Greenoaks and Sequoia to advance AI-designed oncology and immunology drugs to clinical trials.

By Dillip Chowdary • Nov 17, 2026 • Source: TechCrunch

Isomorphic Labs raises $5 billion as it looks to take drug candidates
Image: TechCrunch

At a glance

Product
AI drug-design engine
Round
Series C funding round
Amount
$5 billion
Founding
Spun out of DeepMind in 2021
CEO
Demis Hassabis
Prior round
$2.1 billion Series B in May

Isomorphic Labs has secured $5 billion in a Series C funding round to advance its computationally designed drug candidates into human clinical trials, according to TechCrunch's report. The London-based biotechnology business was established in 2021 as a spin-out from Alphabet's artificial intelligence research laboratory Google DeepMind. This fresh capital infusion represents one of the largest private financing events across the biotechnology and artificial intelligence industries to date.

This analysis details the capital structure of the transaction, the mechanical operation of the underlying predictive chemistry platform, and the enterprise commercial partnerships currently active across global pharmaceutical manufacturing. It also examines the organizational realignment of executive leadership and the operational roadmap required to move computational candidates into hospital trial sites. Biomedical engineers, institutional investors, and pharmaceutical research teams can evaluate how the capital accelerates computational drug design programs.

01Capital syndicate and sovereign backing

The Series C transaction was co-led by investment firms Greenoaks and Sequoia Capital, establishing broad institutional backing across Silicon Valley venture groups. Silicon Valley firm Andreessen Horowitz joined the company as a new institutional investor alongside the lead entities. Multiple additional private capital partners also participated in the syndicate to complete the five billion dollar financing round.

All existing institutional backers from previous financing cycles elected to inject follow-on capital during this investment round. Alphabet backed the subsidiary through its dedicated venture capital operations, GV and Capital G, maintaining parent corporate alignment. Private investment groups Thrive Capital, MGX, and Singapore sovereign investment entity Temasek joined the round alongside the UK Sovereign AI Fund.

This round arrives on the heels of a $2.1 billion Series B financing completed in May earlier this year. The company plans to allocate the incoming balance sheet capital toward expanding the core drug-design software and pursuing additional disease categories. The leadership team will also fund laboratory operations to satisfy clinical trial regulatory submissions.

02Predictive simulation and structural chemistry models

Isomorphic Labs develops an automated drug-design engine that relies on specialized simulation artificial intelligence models to evaluate atomic interactions across biological targets. These computational systems explore distinct disciplines within molecular chemistry to help staff research scientists engineer targeted chemical compounds. The underlying software pipelines aim to compress the discovery timeline required to identify viable therapeutic molecules.

The technological architecture directly extends the foundational achievements of AlphaFold, the breakthrough protein-folding platform developed within Google DeepMind. AlphaFold predicts the complete three-dimensional structures of target proteins directly from linear genetic sequences without empirical crystallography. Isomorphic Labs utilizes these molecular shape predictions to generate custom chemical structures tailored to lock into designated cellular sites.

The engineering team intends to deploy the fresh capital to broaden the simulation engine into a wider variety of human medical disciplines. Expanding the underlying algorithmic simulations will allow the system to predict how candidate compounds interact across more complex biological environments. This technical approach seeks to replace legacy empirical trial-and-error chemistry screening with verified mathematical predictions.

03Oncology validation and multinational pharmaceutical agreements

Advertisement

Tech Pulse Daily

Get tomorrow's pulse first

Join engineers who read Tech Pulse before stand-up. Free, weekday mornings.

The proprietary drug-design platform has achieved positive preclinical results within the therapeutic fields of oncology and immunology. Those laboratory benchmarks confirm that computationally generated chemical candidates demonstrated measurable biological activity against targeted disease markers in non-human testing. Successful preclinical verification provides the necessary evidentiary foundation required to transition experimental molecules toward human subject evaluation.

To commercialize its discovery engine, Isomorphic Labs has established major collaborative agreements with established multinational pharmaceutical manufacturers. The laboratory has finalized strategic development deals with American drugmaker Eli Lilly, Swiss multinational manufacturer Novartis, and healthcare conglomerate Johnson & Johnson. These joint enterprise initiatives pair external pharmaceutical manufacturing capabilities with the London laboratory's generative design algorithms.

Partner organizations leverage the proprietary predictive models to accelerate specific pipeline targets toward formal commercial production. Combining established therapeutic research pipelines with computational molecular generation provides pharmaceutical corporations with novel chemical starting points. The newly secured capital supports the ongoing technical staffing and laboratory resources committed to these multi-year commercial collaborations.

04Executive stewardship and Nobel chemistry laureates

This financing round marks the first fundraising campaign completed since founder and chief executive officer Demis Hassabis stepped down from leading Google DeepMind. Hassabis relinquished his day-to-day managerial duties as the operating head of DeepMind to focus his attention directly on advancing Isomorphic Labs. He transitioned into the role of chairman at DeepMind to maintain strategic continuity across Alphabet's broader intelligence divisions.

Hassabis and former Google DeepMind director John Jumper received the Nobel Prize in chemistry for their development of the AlphaFold architecture. Their academic recognition highlighted the scientific importance of resolving the fifty-year grand challenge of predicting protein structures using machine learning. The operational leadership of Isomorphic Labs now applies that Nobel-winning computational foundation directly to practical pharmaceutical formulation.

Concentrating executive time exclusively on biotechnology enables the leadership team to guide internal molecular programs toward rigorous biological validation. The executive shift demonstrates how Alphabet treats computational drug development as a standalone commercial enterprise rather than an internal academic research initiative. Dedicated leadership oversight will oversee regulatory filings, safety documentation, and clinical governance.

05Clinical development and private equity valuation

The corporate organization intends to deploy the newly acquired proceeds to advance internal pipeline candidates through the clinical trial phase. Progressing from preclinical laboratory assays into clinical investigations represents a major regulatory transition requiring substantial monetary reserves. The financing will fund human patient cohorts, hospital monitoring networks, and compliance reporting needed for regulatory submissions.

Note: Isomorphic Labs did not disclose an official valuation in its financing announcement, but Bloomberg reported earlier this month that the company sought funding at a $50 billion valuation.

Securing five billion dollars provides the balance sheet duration necessary to support lengthy clinical testing cycles without immediate fundraising requirements. Because late-stage clinical programs demand extensive resources, having long-term private capital ensures steady operational execution across global regulatory jurisdictions. The company now enters its next development phase, translating structural predictive algorithms into verified clinical medicines.

Frequently asked questions

How much capital did Isomorphic Labs raise in its Series C round?

Isomorphic Labs raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, following a $2.1 billion Series B round completed in May.

Which pharmaceutical companies have partnered with Isomorphic Labs?

The company has struck strategic commercial agreements with major pharmaceutical manufacturers Eli Lilly, Novartis, and Johnson & Johnson.

What scientific technology serves as the foundation for Isomorphic Labs?

The platform builds on Google DeepMind's AlphaFold protein-folding system, which predicts the three-dimensional structures of biological proteins directly from genetic sequences.

Who leads Isomorphic Labs and what is their background?

The company is led by founder and CEO Demis Hassabis, who won the Nobel Prize in chemistry alongside John Jumper for work on AlphaFold and stepped back from leading DeepMind to focus on drug discovery.

Sources

Dillip Chowdary

Author

Dillip Chowdary

Writes Tech Bytes coverage of AI, engineering, and the tools that actually ship. Editor of Tech Pulse Daily.

Related on Tech Bytes

Advertisement

5-min tech signal

Weekday briefing for engineers who skip the noise.

No spam · Unsubscribe anytime

Advertisement

✈️ CareerPilot

Your AI job-search copilot

Match your resume against live Ashby, Greenhouse & Lever openings — fit scores, job-specific resume optimization and email alerts.

Find matching jobs →

Free Tools

Browse all tools →